Signal · Regulation & Trade
Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability
What the source reported
Source-reportedThe Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage." This guidance assists sponsors in the design and analysis of studies that assess the influence of hepatic impairment on the pharmacokinetics and, where appropriate, the pharmacodynamics of a drug, including therapeutic biological products. When final, this guidance will represent FDA's current thinking. FDA is also withdrawing the guidance for industry titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling" (May 2003), which formerly provided FDA's thinking relating to studies to assess the effect of hepatic impairment on the pharmacokinetics or pharmacodynamics of a drug and recommendations to include hepatic impairment information in labeling.
- Publication
- US Federal Register - FDA (food, drug, device rules) · Government/Regulator
- Published
- 2nd September 2026
- Original report
- federalregister.gov
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Regulation & Trade
- Geography
- United States
- Organisations
- None identified
- Collected
- 28th September 2026 · 16:32
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Low (11.0/100). Strongest contributor: Procurement Impact (6.0/30 points). Limiting factor: Geographic Breadth (0.0/10 points). Initial Confidence Low (39/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (40.0/40 points). Limiting factor: Specificity (0.0/20 points). Capped at 39 (Low) -- insufficient structured evidence to support a higher Confidence reading, regardless of source authority.
- Strongest contributor
- Procurement Impact
- Limiting factor
- Geographic Breadth